QRG Capital Management Inc. Purchases 125,612 Shares of Haleon PLC Sponsored ADR (NYSE:HLN)

QRG Capital Management Inc. increased its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 38.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 451,968 shares of the company's stock after purchasing an additional 125,612 shares during the period. QRG Capital Management Inc.'s holdings in Haleon were worth $4,651,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Brighton Jones LLC purchased a new stake in Haleon during the fourth quarter valued at approximately $187,000. Savant Capital LLC boosted its position in shares of Haleon by 99.2% during the fourth quarter. Savant Capital LLC now owns 26,393 shares of the company's stock worth $252,000 after acquiring an additional 13,142 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Haleon by 11.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 28,474 shares of the company's stock worth $269,000 after acquiring an additional 2,914 shares during the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Haleon by 11.7% during the fourth quarter. Valeo Financial Advisors LLC now owns 20,453 shares of the company's stock worth $195,000 after acquiring an additional 2,141 shares during the last quarter. Finally, Principal Securities Inc. grew its stake in shares of Haleon by 46.4% in the 4th quarter. Principal Securities Inc. now owns 78,878 shares of the company's stock worth $752,000 after buying an additional 24,997 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Down 0.5%

NYSE:HLN opened at $10.45 on Thursday. The company has a market cap of $46.99 billion, a PE ratio of 26.78, a P/E/G ratio of 2.99 and a beta of 0.31. Haleon PLC Sponsored ADR has a twelve month low of $8.25 and a twelve month high of $11.42. The company has a current ratio of 0.98, a quick ratio of 0.78 and a debt-to-equity ratio of 0.53. The company's 50 day moving average is $10.67 and its two-hundred day moving average is $10.09.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HLN shares. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Hsbc Global Res downgraded shares of Haleon from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley raised shares of Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a research report on Friday, May 9th. Finally, HSBC reissued a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Five analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.